CytoDyn Submits Phase IIb Protocol for PRO 140 Clinical Trial to FDA

04-11-2013 Business Wire HealthComments (0)

BiotechnologyCytoDyn

CytoDyn Inc. (“CytoDyn”) (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn’s leading product under development as a treatment for Human Immunodeficiency Virus (HI

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top